Asthma – Access & Reimbursement – Access & Reimbursement – Asthma (US)
The dynamics within the LABA/ICS FDC, LAMA, LABA/LAMA/ICS FDC, and biological drug classes will continue to shape the U.S. asthma market. The dominance of branded LABA/ICS FDCs (e.g., GSK’s Advair, AstraZeneca’s Symbicort) will likely decline further as uptake of generic / branded generic agents strengthens. Each biologic has been carving out its own niche among the subpopulations of severe, refractory asthma, with Roche’s Xolair used in patients with allergic asthma, IL-5 inhibitors and Sanofi / Regeneron’s Dupixent in patients with eosinophilic asthma, and AstraZeneca’s Tezspire in patients independent of TH2 status. However, the 2025 approval of the first ultra-long-acting IL-5 inhibitor (GSK’s Exdensur) may alter the competitive landscape among the IL-5 inhibitors. Overall, marketers of current and emerging asthma agents will face increasing challenges as they strive to retain / gain a favorable formulary position and market uptake in this crowded market.
QUESTIONS ANSWERED
- Which asthma therapies have favorable formulary placement, and how do payers manage the use and costs of these therapies?
- How do reimbursement restrictions affect physicians’ prescribing of LABA/ICS FDCs, AstraZeneca’s Airsupra, Boehringer Ingelheim’s Spiriva, GSK’s Trelegy, and biologics to their asthma patients?
- How do payers / physicians expect emerging inhaled therapies, notably AstraZeneca’s Breztri and Teva’s albuterol / fluticasone propionate, to affect access to / prescribing of current branded therapies, and what are their perceptions of the emerging long-acting anti-TSLP Generate Biomedicines’ GB-0895?
- How are payers covering GSK’s Exdensur, and has it impacted coverage of established IL-5 inhibitors (i.e., GSK’s Nucala, AstraZeneca’s Fasenra)?
PRODUCT DESCRIPTION
Leveraging Clarivate’s proprietary data sources and surveys with physicians and payers, Access & Reimbursement provides integrated brand- and disease-level insight on reimbursement dynamics and the impact of payer policy on physician prescribing behavior in the United States. Through detailed analyses of drug coverage, restriction policies, and contracting, as well as payer and prescriber perspectives on key marketed drugs and their receptivity to emerging therapies, this report enables you to:
- Identify and learn how to overcome roadblocks to market access to best position your brand.
- Identify key stakeholders and reimbursement drivers and assess the impact that reimbursement decisions have on treatment selection.
- Evaluate competitor strategies for securing favorable market access terms.
Geography: United States
Primary research: Survey of 50 U.S. pulmonologists and 50 U.S. allergists, 30 U.S. MCO PDs/MDs, and interviews with 2 U.S. MCO PDs/MDs
Fingertip Formulary: Formulary coverage by commercial plans covering more than 187 million lives nationally.
Real-world data: U.S. pharmacy and medical claims data
Key drugs: Advair, Symbicort, Spiriva, Trelegy, Xolair, Nucala, Cinqair, Fasenra, Dupixent, Tezspire, Exdensur
